Alkermes (NASDAQ:ALKS) Shares Purchased by Rep. Gilbert Ray Cisneros, Jr.

Key Points

• Rep. Gilbert Ray Cisneros Jr. purchased $1,001–$15,000 of Alkermes stock on September 29, according to a disclosure filed October 12. He also bought shares in several healthcare and consumer companies while selling positions in others.
• Alkermes shares opened at $39.73, down 1.3%, with a market capitalization of approximately $6.67 billion. Analysts collectively rate the stock “Moderate Buy,” with an average price target of $54.47.
• Institutional investors own 95.21% of Alkermes, with several major hedge funds increasing their stakes. Meanwhile, company insiders sold about $3.75 million of stock over the past three months.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Alkermes plc (NASDAQ:ALKS). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Alkermes stock on September 29th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of Benchmark Electronics NYSE: BHE on 10/1/2026.
• Sold $1,001 - $15,000 in shares of Oxford Industries NYSE: OXM on 9/29/2026.
• Sold $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 9/29/2026.
• Sold $15,001 - $50,000 in shares of ITT NYSE: ITT on 9/29/2026.
• Sold $1,001 - $15,000 in shares of BridgeBio Pharma NASDAQ: BBIO on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Tandem Diabetes Care NASDAQ: TNDM on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Cytokinetics NASDAQ: CYTK on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Ultragenyx Pharmaceutical NASDAQ: RARE on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of YETI NYSE: YETI on 9/29/2026.
• Sold $1,001 - $15,000 in shares of AtriCure NASDAQ: ATRC on 9/29/2026.

Alkermes Stock Down 1.3%

Shares of Alkermes stock opened at $39.73 on Wednesday. Alkermes plc has a 52-week low of $27.00 and a 52-week high of $55.67. The company has a 50 day moving average of $45.55 and a 200 day moving average of $43.50. The company has a quick ratio of 1.85, a current ratio of 2.30 and a debt-to-equity ratio of 0.82. The company has a market capitalization of $6.67 billion, a P/E ratio of 104.56 and a beta of 0.32.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ALKS shares. TD Cowen reaffirmed a "buy" rating on shares of Alkermes in a research report on Monday, September 21st. Robert W. Baird increased their target price on Alkermes from $58.00 to $61.00 and gave the company an "outperform" rating in a report on Tuesday, September 22nd. Wells Fargo & Company raised their price target on Alkermes from $44.00 to $65.00 and gave the company an "overweight" rating in a research note on Monday, June 29th. HC Wainwright reaffirmed a "neutral" rating on shares of Alkermes in a report on Monday, September 21st. Finally, Bank of America reaffirmed an "underperform" rating on shares of Alkermes in a report on Monday, June 29th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $54.47.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ALKS. Baker BROS. Advisors LP increased its position in Alkermes by 23.7% during the 4th quarter. Baker BROS. Advisors LP now owns 10,012,267 shares of the company's stock worth $280,143,000 after purchasing an additional 1,920,916 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Alkermes by 2.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 4,522,378 shares of the company's stock valued at $159,850,000 after buying an additional 109,595 shares during the period. Commodore Capital LP lifted its holdings in shares of Alkermes by 18.3% in the 1st quarter. Commodore Capital LP now owns 4,200,000 shares of the company's stock valued at $148,512,000 after buying an additional 650,000 shares during the period. First Trust Advisors LP lifted its holdings in shares of Alkermes by 104.2% in the 1st quarter. First Trust Advisors LP now owns 2,968,785 shares of the company's stock valued at $104,976,000 after buying an additional 1,514,783 shares during the period. Finally, Affinity Asset Advisors LLC boosted its stake in shares of Alkermes by 35.0% in the first quarter. Affinity Asset Advisors LLC now owns 1,350,000 shares of the company's stock valued at $47,736,000 after buying an additional 350,000 shares in the last quarter. Hedge funds and other institutional investors own 95.21% of the company's stock.

Insiders Place Their Bets

In related news, EVP Craig C. Hopkinson sold 9,000 shares of the firm's stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $46.99, for a total value of $422,910.00. Following the completion of the sale, the executive vice president owned 65,389 shares in the company, valued at $3,072,629.11. This trade represents a 12.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy Lynn Md Snyderman sold 44,472 shares of Alkermes stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $50.35, for a total transaction of $2,239,165.20. Following the sale, the director owned 15,395 shares of the company's stock, valued at approximately $775,138.25. The trade was a 74.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 76,150 shares of company stock valued at $3,752,181 in the last three months. 4.59% of the stock is owned by corporate insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system diseases. The company's portfolio addresses conditions including addiction, schizophrenia, bipolar disorder and amyotrophic lateral sclerosis (ALS), with an emphasis on long-acting injectable, extended-release and other drug-delivery technologies.

Its marketed products include Vivitrol, an extended-release injectable formulation of naltrexone used to treat alcohol dependence and prevent opioid dependence relapse; Aristada, a long-acting injectable formulation of aripiprazole lauroxil for the treatment of schizophrenia in adults; Lybalvi, an oral combination of olanzapine and samidorphan for schizophrenia and bipolar I disorder; and Exservan, an oral film formulation of riluzole for ALS.

Founded in 1987, Alkermes is headquartered in Dublin, Ireland, with operations and corporate offices in the United States, including Waltham, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.